Charles River Laboratories (CRL) Tops Q3 EPS by 9c, Offers Guidance

Go back to Charles River Laboratories (CRL) Tops Q3 EPS by 9c, Offers Guidance

Charles River Labs (CRL) PT Raised to $250 at Jefferies

November 3, 2022 8:14 AM EDT

Jefferies analyst David Windley raised the price target on Charles River Labs (NYSE: CRL) to $250.00 (from $240.00) while maintaining a Buy rating.

The analyst commented, "In broad strokes, the composition of CRL's strong report was as we expected in our upgrade. Consolidated... More

Charles River Laboratories (CRL) Announces Avian Vaccine Divestiture

November 2, 2022 7:21 AM EDT

Charles River Laboratories (NYSE: CRL) announced that it has signed a definitive agreement to divest its Avian Vaccine business for approximately $170 million in cash with potential contingent payments of up to an additional $30 million, subject to certain closing adjustments.

The Avian... More